Sugi Predict

Sugi Predict / Compounds / SCHEMBL2860409

SCHEMBL2860409

SCHEMBL2860409

Cc1c(OCCC(=O)O)cccc1-n1nc2c(c1N)c(=O)[nH]c1ccccc12

nearest known ligand 0.37

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
▸ ADORA3 P0DMS8 5/20 0.37
▸ LMNA P02545 1/20 0.36
▸ CHEK1 O14757 1/20 0.36
▸ MCL1 Q07820 3/20 0.35
▸ ALB P02768 1/20 0.35
▸ BCL2 P10415 1/20 0.35
▸ KDM4E B2RXH2 2/20 0.34
▸ MAPK1 P28482 1/20 0.34
▸ HSD17B10 Q99714 1/20 0.34
▸ FABP3 P05413 1/20 0.33
▸ ADORA1 P30542 1/20 0.33
▸ ATM Q13315 1/20 0.33
▸ PARP1 P09874 1/20 0.33
▸ PARP2 Q9UGN5 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2871427 0.91 CHEK1 (0.39) ADORA3CHEK1KDM4EFABP3
SCHEMBL2871372 0.90 ADORA3 (0.39) ADORA3LMNACHEK1KDM4EADORA1
SCHEMBL2863007 0.88 SCN9A (0.39) ADORA3CHEK1KDM4EADORA1
SCHEMBL2864837 0.86 DDB1 (0.41) ADORA3CHEK1KDM4EHSD17B10ATM
SCHEMBL13025378 0.86 DDB1 (0.39) ADORA3CHEK1KDM4EHSD17B10
SCHEMBL2865235 0.84 ABCG2 (0.43) ADORA3CHEK1KDM4EADORA1ATM
SCHEMBL2862965 0.84 PDE10A (0.40) ADORA3CHEK1KDM4E
SCHEMBL2867321 0.83 KDM4E (0.39) ADORA3CHEK1KDM4EHSD17B10FABP3
SCHEMBL2866943 0.83 CHEK1 (0.36) ADORA3CHEK1KDM4EHSD17B10
SCHEMBL2870391 0.82 DDB1 (0.39) CHEK1MCL1ATM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8741894-B2 Arylsulfonamide CCR3 antagonists AXIKIN PHARMACEUTICALS, INC. (US) 2014-06-03 — — US disclosed
US-7842701-B2 Pyrazoloquinolone derivative and use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-11-30 — — US disclosed
US-7842701-B2 Pyrazoloquinolone derivative and use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-11-30 — — US disclosed
US-7842701-B2 Pyrazoloquinolone derivative and use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-11-30 — — US disclosed
US-20070281963-A1 Pyrazoloquinolone Derivative And Use Thereof TAKEDA PHARMACEUTICAL COMPANY (JP) 2007-12-06 — — US disclosed
US-20070281963-A1 Pyrazoloquinolone Derivative And Use Thereof TAKEDA PHARMACEUTICAL COMPANY (JP) 2007-12-06 — — US disclosed
US-20070281963-A1 Pyrazoloquinolone Derivative And Use Thereof TAKEDA PHARMACEUTICAL COMPANY (JP) 2007-12-06 — — US disclosed
EP-1719771-A1 PYRAZOLOQUINOLONE DERIVATIVE AND USE THEREOF Takeda Pharmaceutical Company Limited (JP) 2006-11-08 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070281963-A1 Pyrazoloquinolone Derivative And Use Thereof MAP3K20, MAP4K5, MAP4K3 ADORA3 1829/4885LMNA 4123/4885CHEK1 605/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.